|
Molecular and sub-molecular research investigation and modeling are currently the main core for biotechnological and medical advances in the 21st Century. This is continuously achieved by advancing routine and establishing novel methods, procedures, strategies and principles for answering practical questions from the complexities of living organisms and physiological processes. The modern fundamental research and applied medical practice are now more than ever focused on molecular level detecting, finding and purifying individual genes, proteins and their associations. Further advances on molecular biotechnological level have to relay not only on routine detection, crystallographic and genetical methods, but based on novel approaches, conceptions and methodologies capable of providing information about sub-molecular and quantum changes in the conformational behavior and energy-transfer relations between molecules in vivo in order to solve ultimate biological challenges such as: how could be explained the behavior, function, structure, and evolution of cells or particular biological processes? Major unanswered questions include the following: 1) What are the mechanisms of integration and coordination between the wide-ranges and types of bio-molecules (proteins, nucleic acids, carbohydrates, and small organic molecules) to allow the maintenance of different functional processes in the cells and organism systems? 2) What enables the cell key properties of adaptation to a wide range of perturbations in their genotype and environment? 3) What are the evolutionary mechanisms for the changes in the molecular structures and interactions that serve as a purpose for organism adaptation and exploration of long term environmental changes? 4) What are the genetic and structural mechanisms maintaining the balanced coexistence of short-term cell/organism robustness with long-term adaptability? We believe that there are design principles to be discovered in biology, which will help to address the major questions of how living organisms work.
Our goals are the novel design and major improvement of critically important biological methodologies and techniques, discovery of more advanced principles, technologies, devices and products dedicated to further improvements in medical and biotechnological research.
Current research Complex Genomic Information Research Regon Molecular Systems, Inc. is dedicated to developing state-of-the-art technologies for acquiring, analyzing and managing complex genetic information for use in biomedical research. Several original inventions (patents pending) are basis for the development of series of products and services including technology for NewGeneration Ô highly-representative cDNA Library preparation that include enhanced representation of so called poly-A- mRNAs [click here to link]; three different surface preparation technologies for nucleic-acid, protein and tissue microarrays demonstrating outstanding efficiency and speed under most moderate conditions [click here to link]; technology for genomic mapping (from single gene to entire unknown genomes) via oligonucleotide fingerprinting (Dyanov H.M., Salbego, Savkovic, S., Kreuzer, H, Serrato, H., Batus, S., Grujic, D., Zeremski, M., Strezoska, Z., Paunesku, T., Little, S., Kourtev, M., and Dyanova, P. (2004) In a Search for New Genes: Arrayed cDNA Library Characterization by Oligonucleotide “Fingerprinting“-Hybridization. Regon Scientific Journal, 105 [Array Technology] (1): 2; www.regonjournal.com.) dedicated to anti-bio-terrorism via preparation of universal microarray for border patrol against all known-, potential- and even unknown medical pathogens and ecologically destructive species.
Oligonucleotide Annealing and Primed Polymerase Reactions Oligonucleotide annealing process and kinetics plays critical role, practically, in all related diagnostics and research applications including RT-PCR and all PCR variations from very-small target-sample amounts, all nucleic acid-based microarray- and in-situ hybridization reactions and labeled probe preparations and many other reactions and methodologies implementing complementary binding reactions of nucleic acids, usually called annealing reaction. Entirely new original conditions for significant annealing improvement and enhancement were discovered and are basis for original (Reverse Transcription) RT-Machine construction. These lead to 5-10-times RT-product yield increase for total RNA target amounts below 1 microgram (down to 1 pg) and 5-10 times annealing time increase for all annealing (hybridization) reactions with increasing the amounts of annealed probe nucleic-acid. In comparison, the regular RT primer annealing with total RNA amounts below 100 ng is so unefficient, that practically does not exist for the very-low-expressed mRNAs making the microarray applications irrelevant due to both low sensitivity and reproducibility.
Nucleic Acids, Protein, Small Molecule and Tissue Arrays. Microarrays were invented to study RNA binding to spots of cDNA, but the same basic principle can be applied to the problem of detecting protein-protein interactions or proteins that bind to chemicals. We have developed most advanced chemistries, surfaces and general methods for arraying either nucleic acids, proteins or chemicals on glass slides, using an original surfaces and technology – advantageous, it attaches the structures in real-time, immediately upon contact with the surface.
Developing and marketing proprietary DNA probe based tests to clinicians and researchers. DNA Probe tests can be powerful diagnostic tools applicable to viral and bacterial diseases, including sexually transmitted diseases, as well as cancer. Because they work at the genetic level, DNA probes have the potential to facilitate earlier and more definitive diagnoses. This is especially important in AIDS diagnosis and testing. Antibodies to HIV, the virus that causes AIDS, often appear several months after initial infection. Because detection of DNA can be made independent of the presence or absence of antibodies, presence of the virus can be determined much earlier after infection. Regon Molecular Systems, Inc. primary market focus is infectious disease diagnostics and genetic abnormality detection. The company has developed an integrated portfolio of proprietary technologies, each affording a variety of diagnostic applications. Of particular importance is the patented technology for DNA labeled with special nonradioactive signaling molecules. This pioneer technology has made possible the development of cohesive systems based on DNA for early diagnosis. These RegonProbe Detection Systems are similar in sensitivity to radioactive probes, yet have a longer shelf life and possess less health risk and disposal problems than do the radioactive ones. Regon’s nonradioactive tests use DNA probes to identify viruses and other infectious disease pathogens, and cancer markets. The company's Regon-PathoGene product line contains products which pinpoint under the microscope exactly which cells are infected and where in the cell the infection is located, making them especially well suited for pathologists and cytotechnologists.
Regon's diagnostic strategy has been to secure a technology position enabling the company to fully develop the potential of genetic-based diagnosis. The success of this approach is evidenced by the diversity and breadth of the Company's patents and pending applications. Regon Molecular Systems, Inc. has proprietary technologies for making products in a variety of formats, including solid-matrix hybridization, in situ products, and those that are solution based or in suspension. Moreover, a variety of technologies for detection systems have been devised. Regon can now create tests that are detectable by visualization, spectroscopy, radiography, flow cytometry or fluorescence. Many of these detection systems can be readily automated. With Regon Molecular Systems, Inc. pioneering technological efforts, nonradioactive DNA detection has matured to a state where direct detection of pathogens in clinical samples can be accomplished in a timely and cost-effective manner. Future research Genetic and Phenotypic Diversity in Natural Populations We would like to study diversity within populations, the relationship between genotypic and phenotypic diversity, and how genotypic and phenotypic diversity change in response to environment. Over the next few years, Regon Molecular Systems, Inc. will be expanding to a steady-state size of approximately 50 researchers, and our research areas will also expand and diversify. Some of the topics Regon hopes to address in the short to medium term are listed below.
◊ Biological Networks ◊ Theory & Databases ◊ Chemical Genetics
With Regon's futures pioneering technological efforts, nonradioactive DNA detection has matured to a state where direct detection of pathogens in clinical samples can be accomplished in a timely and cost-effective manner by utilizing universal microarray-based kits.
Regon Molecular Systems, Inc., headquartered in Chicago, Illinois, is a privately held company focused on the detection, measurement and analysis of biological interactions, which serves as the fundamental basis for a broad array of in vitro test systems within the pharmaceutical, biotechnology, genomics and diagnostics industries. Regon Molecular Systems, Inc. has developed the NewGeneration Technology™, an ultra-enhanced signal generation and detection platform technology for the simple and efficient detection, measurement and analysis of biological interactions. The Company provides "open access" to its technology products. For more information, please visit our web site at www.regon-inc.com.
|
